Q-omics provides the consensus-scored GAPDHP58 profile across patient tissues and cancer cell-line models. GAPDHP58 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, GAPDHP58 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, GAPDHP58 RNA expression shows 14,401 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, KIRC, and GBM as cancer lineages where GAPDHP58 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP58 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP58 survival associations across molecular data types. GAPDHP58 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP58 RNA expression–survival associations across cancer types. High GAPDHP58 expression shows unfavorable associations in LUAD, LIHC, LGG, MESO and PAAD, but favorable associations in THCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify LUAD as the clearest survival context for GAPDHP58 RNA expression.
This table summarizes GAPDHP58 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP58. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP58 shows higher tumor expression in KIRC, HNSC, LIHC, COAD, LUSC and BRCA. The KIRC box plot shows higher GAPDHP58 RNA expression in tumor versus normal tissue (log2 FC = +0.113, t-test p < 0.001).
This table shows molecular features associated with GAPDHP58 in patient tissues and cancer cell lines. In patient samples, GAPDHP58 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
